AGTC is developing a recombinant adeno-associated virus (rAAV) vector AGTC-501, also designated AAV2tYF-GRK1-RPGRco, to treat retinitis pigmentosa (RP) in patients with mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. The vector contains a codon-optimized human RPGR cDNA (RPGRco) driven by a photoreceptor-specific promoter (G protein-coupled receptor kinase 1, GRK1) and is packaged in an AAV2 capsid with three surface tyrosine residues changed to phenylalanine (AAV2tYF). We conducted a safety and potency study of this vector administered by subretinal injection in the naturally occurring RPGR-deficient Rd9 mouse model. Sixty Rd9 mice (20 per group) received subretinal injection in the right eye of vehicle (control) or AAV2tYF-GRK1-RPGRco at one of two dose levels (4 × 10 8 or 4 × 10 9 vg/eye) and were followed for 12 weeks after 
This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. at early ages, progressive loss of ERG amplitudes with aging and decline in visual acuity. [4] [5] [6] A study of 113 males with RPGR mutations reported the mean annual exponential rate of decline was 4.0% for visual acuity, 4.7% for visual field area and 7.1% for ERG amplitude, and the median age at which patients reached legally blind status, based on loss of acuity and/or visual field, was 45 years. 6 There are multiple alternatively spliced transcripts of the RPGR gene, two of which have been extensively studied. The constitutive transcript, RPGR [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , is widely expressed in many cell types, including in the retina 7 . An alternatively spliced transcript containing exons 1 to 15 and a large part of intron 15, RPGR-ORF15, most abundant in the retina in all species examined 8 , is localized in the connecting cilia of rod and cone photoreceptors.
Toxicology and Pharmacology of an AAV Vector Expressing Codonoptimized RPGR in RPGR-deficient Rd9 Mice
Some RPGR-ORF15 can also be detected in the outer and inner segments. 9, 10 The highly repetitive purine-rich ORF15 region encodes glutamate and glycine repeats and is a mutation hotspot, accounting for up to 80% of all reported RPGR mutations. 8, 11 The physiological role of the RPGR-ORF15 protein is not fully elucidated, although it is likely involved in regulating transport through the photoreceptor cilium. 3, 12, 13 Proof of concept studies in XLRP mouse and dog models have shown that subretinal delivery of recombinant adeno-associated virus (rAAV) vectors expressing a RPGR-ORF15 transgene can maintain photoreceptor structure and function. [14] [15] [16] To treat patients with retinitis pigmentosa caused by mutations in RPGR, AGTC is developing a rAAV viral vector (AAV2tYF-GRK1-RPGRco, or AGTC-501), which is an AAV2 capsid with three tyrosine to phenylalanine mutations on the capsid surface and contains a codon-optimized human RPGR-ORF15 gene driven by photoreceptor-specific promoter (G protein-coupled receptor kinase 1, GRK1). As part of our efforts to develop this vector for use in patients, we conducted a study in the naturally occurring RPGR-deficient Rd9 mouse model to evaluate vector safety by standard GLP-compliant toxicology methods, vector This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
potency by determining dose-related protein expression and localization in vivo, and vector stability by DNA, RNA and protein sequence in retinal tissues or transfected cells.
RESULTS AND DISCUSSION

Objective and Study design
The study was designed to evaluate the safety and pharmacology of rAAV2tYF-GRK1-RPGRco administered by subretinal injection in RPGR-deficient Rd9 mice, a naturallyoccurring model of XLRP caused by mutations in RPGR-ORF15. The retinal phenotype of Rd9 mice is relatively mild when compared to that of RPGR-XLRP patients, yet it shares important features with the human disease, including similar retinal pathology and reduction of ERG function at an early age. 17 All procedures in the protocol were in compliance with applicable animal welfare acts and were approved by the local Institutional Animal Care and Use Committee (IACUC).
Sixty Rd9 mice, including hemizygous males and homozygous females, 6-8 weeks of age, in three groups of 20 animals each, were used in the study (Table 1) The primary safety endpoint of this study was the histopathology examination of tissues. Clinical observations, including body weights, ocular exams, assessments of hematology, clinical chemistry parameters and ERGs, were also performed. Additional evaluation included immunohistochemical staining for RPGR, measurement of serum antibodies to RPGR in specimens collected at euthanasia, and the sequence integrity of the codon-optimized RPGR at both the mRNA and protein level. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Summary of Data
Ophthalmic examination
A summary of the ophthalmic findings for each group is presented in Supplementary 2 . It has been reported that at scotopic condition, the dimmer flashes generate an ERG b-wave driven by rod postreceptoral activity, whereas the brighter flash produces an a-wave dominated by rod photoreceptor activity and a bwave that is driven by both rod and cone postreceptoral neurons 18 . For scotopic ERG, we plotted b-wave amplitudes at all three light intensities and a-wave amplitudes at 2.5 cds/m2. There was a trend toward ERG amplitude reduction (both a-wave and b-wave) in animals administered with the higher vector dose. There was a large animal-to-animal variation, however, no statistically significant differences between the treated and untreated eyes were found (p>0.05) (Figure 1 ). It has been reported that administration of a rAAV-RPGR vector at high doses can cause photoreceptor degeneration 15, 19 , and the possibility of toxicity from the high dose of the AAV2tYF-GRK1-RPGRco vector will be considered during the design of clinical studies. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
All eyes were considered for statistical analysis including the five injected eyes (1 vehicle control, 1 low dose and 3 high dose injected eyes) that showed a near to flat ERG under scotopic and photopic conditions. The near to total loss of ERG signal in these animals was considered likely related to injection-related damage.
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variability within and among groups, including controls, and across time points. These increases were most likely artifacts of handling rather than effects of the test article 21 .
Post-mortem findings
No vector-related changes in absolute or relative organ weight parameters and no vectorrelated macroscopic findings were observed at either Week 4 or Week 12.
Ocular Histopathology
No vector-related histopathology findings were observed at Weeks 4 or Week 12. All findings were considered to be procedure related or incidental findings. In addition, swollen lens fibers and/or lens fibrosis were present in <10% of injected eyes. Because each of these findings were present in all groups, including the vehicle control group, and lacked a dose response relationship, they were considered related to the subretinal injection procedure and not related to the test article.
RPGR expression
Vector-induced RPGR expression occurred in a time-and dose-dependent manner. At Table 4 ).
Although the function of RPGR-ORF15 in the retina is not fully understood, studies
suggest that RPGR-ORF15 may act as a ciliary gate, or participate in cargo trafficking and sorting in the transition zone of photoreceptor cells. 3 To function correctly, RPGR-ORF15 must be localized at the correct subcellular compartment, predominantly in the connecting cilium of human and mouse photoreceptors. Detectable RPGR-ORF15 can also be found in No RPGR protein labeling was detected in the vehicle control-treated eyes ( Figure 2 , panel A), which is consistent with a previous report. 17 
Antibodies to vector-expressed RPGR protein
Sera collected at the Week 4 and Week 12 sacrifice time points from all animals were tested for antibodies to human RPGR protein by ELISA, and all samples tested were negative.
Stability of RPGRco cDNA and mRNA
Due to the highly repetitive nucleotide sequence composition of the RPGR-ORF15 region, unusually high rates of mutation and complex splicing patterns have been extensively reported. 1, 19, 22 To overcome this challenge for developing a rAAV vector, the 3,459-bp coding sequence of RPGR-ORF15 was codon optimized based on human codon usage and further modified to reduce tandem repeats, increase the frequency of human codon usage and adjust G/C content to prolong mRNA half-life, as described in our previous publication. 22 We previously verified the stability and fidelity of the RPGRco cDNA sequence by DNA sequencing at multiple steps including the large-scale AAV production. 22 In the current study, we further confirmed the sequence integrity of the codon-optimized To confirm that codon-optimized RPGR-ORF15 cDNA did not result in changes to the amino acid sequence, immunoprecipitated RPGR-ORF15 protein from HEK293 cells transfected with AAV plasmid pTR-CB-RPGRco was separated by SDS-PAGE ( Figure 3B ), and the protein bands were excised and subjected to enzymatic cleavage for subsequent peptide sequence analysis by LC-MS/MS. Using this methodology, 76% of human RPGR-ORF15 protein sequence was confirmed to be 100% identical to the reference sequence, including the C-terminal sequence ( Figure 3C ). For the other 24% of the protein, the special arrangement of limited proteolytic sites in the highly repetitive glutamate-glycine C-terminal region resulted in either too large or too small peptide fragments to be detected by LC-MS/MS. Endoproteinase Glu-C partial digestion was also attempted to produce appropriately sized oligopeptides through partial digestion. Due to the highly repetitive glutamate-glycine sequence of RPGR-ORF15, however, it was impossible to determine their precise localizations even when some fragments were identified.
In addition to the full-length RPGR-ORF15, western blot detected a shorter and weaker RPGR band (~140 kDa) in Rd9 retinas injected with AAV-RPGRco ( Figure 3 , arrow head).
After immunoprecipitation and proteomic analysis by LC-MS/MS, the shorter band was determined to contain RPGR exons 1-14 and the C-terminal end of ORF15
(LKNGPSGSKKFWNNVLPHYLELK) (68% coverage, data not shown), indicating an in-frame deletion in ORF15. The 140 kDa protein is one of the multiple RPGR-ORF15 protein isoforms detected in human retina 7 . Apparently, a protein band of the similar size to the 140 kDa protein was also detected by immunoblot in the lysates of HEK293 cells transfected with codon optimized or wild-type RPGR-ORF15 plasmid 23 . The details of how this isoform is generated are not clear currently due to the lack of the complete amino acid sequence information. However, in-frame deletions or insertions in RPGR-ORF15 that retain the C-terminal end have been reported to be well tolerated, 14 and we speculate that This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
both of the full-length and shorter RPGR species expressed in Rd9 mouse from the AAV vector may be functional. PTED
Glutamylation of vector-expressed RPGR protein
Glutamylation, a novel post-translational modification of proteins, was initially observed on structural proteins such as α-and β-tubulins 24, 25 . RPGR-ORF15 was recently identified as a substrate for glutamylation and was shown to be important for its function 26 . We used GT-335, a monoclonal antibody specific for glutamylation, to demonstrate that AAV- 
Interaction of vector-expressed RPGR and RPGR-interacting protein 1 (RPGRIP1)
RPGRIP1 is one of the well-known proteins that binds to RPGR through the C-terminal RPGR-interacting domain. 3 Moreover, the co-localization of RPGR and RPGRIP1 in the connecting cilia of photoreceptors also suggests the importance of their interaction in maintaining proper RPGR function. It has been reported that RPGR mutations impair the interaction between RPGR and RPGRIP1 in vivo, 27 and this interaction is considered to be required for normal RPGR function in photoreceptor cells. We assessed the interaction of vector-expressed RPGR-ORF15 and RPGRIP1 in HEK 293 cells transfected with the respective expression constructs, pTR-SmCBA-RPGRco and/or pCMV-RPGRIP1-Flag (a Cterminal Flag-tagged RPGRIP1 plasmid). Co-immunoprecipitation of whole lysates of transfected HEK293 cells demonstrated that full length RPGR interacts with RPGRIP1 as expected ( Figure 5 ). Since the polyclonal anti-RPGR antibody that we used for Western blots can also weakly interact with RPGRIP1 nonspecifically when used in coimmunoprecipitation experiments, we then switched to a new anti-RPGR antibody which is monoclonal and specifically binds to RPGR only. This new antibody, however, could not efficiently pull down the short band of RPGR (~140kDa) in co-immunoprecipitation, thus we could not conclude whether the short species can also bind to RPGRIP1. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
CONCLUSIONS
The objectives of this study were to evaluate in a naturally occurring mouse model of XLRP, the safety and pharmacology of a viral vector designed to treat XLRP patients by gene augmentation therapy. The viral vector used in this study, designated AGTC-501 or rAAV2tYF-GRK1-RPGRco, contains a codon-optimized human RPGR-ORF15 cDNA driven by a photoreceptor-specific GRK1 promoter, packaged in an AAV2tYF capsid, and manufactured using a herpes simplex virus (HSV)-based AAV production system.
Subretinal injection of AAV2tYF-GRK1-RPGRco at two dose levels (4 × 10 8 and 4 × 10 These results support the use of rAAV2tYF-GRK1-RPGRco in clinical studies in patients with XLRP caused by RPGR mutations.
MATERIAL AND METHODS
AAV vector design and production
Details of the design of the RPGRco cDNA and the rAAV2tYF-GRK1-RPGRco vector were described in a previous publication. 22 The This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
amino acid sequence is identical to the NCBI reference sequence NP_001030025 and CCDS 35229.1.
The vector used in this study was produced using a recombinant HSV complementation system in suspension-cultured baby hamster kidney (sBHK) cells, as previously described.
14
The vehicle was the balanced salt solution (BSS, Alcon, Fort Worth, TX) containing 0.014%
Tween-20. 
Vector characterization
Vector administration
Subretinal injections were performed in anesthetized animals as previously described. 29 Briefly, under direct visualization of a surgical microscope, an incision was made in the cornea using a 30-gauge MVR blade, and a 33-gauge blunt-tipped needle was inserted through the corneal incision toward the back of the eye while avoiding the lens and penetrating the neuroretina to reach the subretinal space. One microliter (1 μL) of vector suspension or vehicle, each containing 0.1% fluorescein to allow confirmation of the injection location, was slowly injected subretinally while the retina was visualized to confirm successful dosing. If reflux of greater than 25% of the dosing volume occurred, as determined by the surgeon occurred, the animal was excluded from the study and replaced. Residual dosing formulations were frozen for later testing by qPCR to confirm the concentration of vector administered. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Ophthalmic examination
Masked ocular observations by the surgeon were made to evaluate complications from the injection procedure or bleeding within the first week and masked results were provided to the Sponsor. After Sponsor's review of the masked findings, extra animals were removed from the study by Day 7.
Animals were observed daily for mortality and signs of illness. Body weights of each animal were obtained on the day of dosing, weekly thereafter, and on the day of scheduled sacrifice. Ophthalmic examinations, used to evaluate the eyes for signs of toxicity by slit lamp biomicroscopy and indirect ophthalmoscopy, were conducted during the week prior to scheduled sacrifice by a licensed veterinary ophthalmologist who was blinded to dose group. Abnormalities were described using standard terminology.
ERG
Scotopic and photopic ERG tests were performed on both eyes. Animals were dark- 
Clinical chemistry, histopathology and immunohistochemistry
At sacrifice, blood for hematology (hemoglobin, hematocrit, neutrophils, lymphocytes, monocytes, eosinophils, basophils, red cell count, platelet count, and white cell count) and clinical chemistry (ALT, AST, blood urea nitrogen, total protein, alkaline phosphatase and albumin: globulin ratio), and serum for immunogenicity analysis (measurement of antibodies) were obtained. A complete external and internal examination was performed on all animals, including body orifices and cranial, thoracic, and abdominal organs and tissues. Brain, heart, liver, kidneys, spleen, thymus, lungs (with large bronchi), adrenals, and testes/ovaries were weighed. Sections of the following tissues were stained with hematoxylin and eosin and examined histologically: injected and uninjected eye with optic nerve, brain, liver, spleen, heart, lung, kidneys, parotid glands, testes/ovaries, and gross This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
lesions. The following tissues were collected for potential histopathology: adrenal gland, cecum, colon, diaphragm, duodenum, epididymis, esophagus, femur with bone marrow, gallbladder, ileum, jejunum, lymph node, pancreas, sciatic nerve, pituitary, prostate, skeletal muscle, skin, stomach, thymus, thyroid/parathyroid gland, urinary bladder. Nonocular histology would be performed based on gross findings.
All gross findings from different organs were recorded in descriptive terms including locations(s), size, shape, color, consistency, and number. All eyes were collected into 
RPGR stability test
Stability of the codon-optimized RPGR was assessed by DNA sequencing, mRNA This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
genome sequences including the GRK1 promoter and RPGRco cDNA was amplified using Platinum PCR SuperMix High Fidelity (ThermoFisher Scientific, Grand Island, NY). The PCR products were then cleaned up using DNA Clean & Concentrator™-5 (Zymo Research, Irvine, CA) and sent for Sanger sequencing performed at Eurofins Genomics (Huntsville, Alabama). The Sanger sequencing reads were then assembled de novo using ContigExpress and aligned to a reference sequence using AlignX, both of which are components of Vector NTI software.
RPGRco mRNA transcribed from AAV vector was sequenced after reverse transcription.
Briefly, retinal tissue from uninjected and vector-injected eyes were processed for RNA extraction (Qiagen, Germantown, MD) and the resulting total tissue RNA was used as template for reverse transcription followed by PCR amplification. The amplified PCR products were then sequenced and all sequencing data were assembled based on the overlapping cDNA fragments using Vector NTI software, to generate a consensus sequence that was compared to the human RPGRco reference sequence for analysis.
Stability of vector-expressed RPGR protein was analyzed by western blot and residues). A decoy database was searched to determine the false discovery rate (FDR) and peptides were filtered according to the FDR.
Statistical Analyses
Hematology, coagulation, and clinical chemistry data were analyzed using analysis of variance and Dunnett's test. Organ weights and ERG were analyzed using analysis of variance and Tukey's multiple comparison test.
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